Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19
Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing Immunochina Medical Science & Technology Co., Ltd.